賽諾菲安萬特 SNY 深 滬
已收盤 08-07 16:00:00 美东时间
43.46
+0.570
+1.33%
華盛通- 最 高43.865
- 今 開43.57
- 成交量 276.63万股
- 最 低 43.34
- 昨 收 42.89
- 總市值 1055.29亿
- 52周最高 50.9152
- 市盈率 靜 18.14
- 換手率 0.11%
- 52周最低 40.89
- 委 比 -91.04%
- 總股本 24.28亿
- 歷史最高 56.7515
- 量 比 0.96
- 振 幅 1.22%
- 歷史最低 13.672
- 每 手 1
- 風險率 2.07%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多赛诺菲安万特(SNY)尼塞韦单抗新适应症上市申请获CDE受理
经济观察网 赛诺菲安万特（SNY）合作研发的尼塞韦单抗注射液新适应症上市申请获CDE受理，目前该药市场竞争较为激烈，短期对业绩贡献有限。 近期事件： CDE官网...
08-08 05:36
药物受理最新动态：Sanofi Winthrop Industrie尼塞韦单抗注射液进口申请获受理
国家药品监督管理局药品审评中心数据显示，2026年8月7日，Sanofi Winthrop Industrie的尼塞韦单抗注射液申请已获受理，受理号为JXSS...
08-07 14:15
全球首款mRNA流感疫苗获FDA批准 莫德纳押注下一代疫苗市场
①美国FDA批准莫德纳全球首款mRNA季节性流感疫苗mFLUSIVA，适用50岁及以上人群； ②因错过2026年美国流感季采购周期，该疫苗预计2027年下半年才会产生明显商业收入。
08-07 03:46
Sanofi India posts robust Q2 2026 results, revamps board committees
An announcement from Sanofi India Limited ( ($IN:SANOFI) ) is now available. Sa...
08-04 23:16
Nurix Therapeutics Earns $10M Milestone Payment Following Initiation Of Sanofi's Phase 1 Clinical Study Of SAR448272/NX-3911
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that it has earned a $10 million milestone payment following the initiation by its collaborator, ...
08-04 19:14
Sanofi’s MenQuadfi approved in EU for infants against meningococcal disease
Sanofi (SNY) received European Commission approval to expand MenQuadfi’s indication to infants aged six weeks and older for protection against invasive meningococcal disease caused by Neisseria mening...
08-04 17:12
Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Nurix Therapeutics and Roche have initiated a global Phase 3 trial, DAYBreak CLL-306, to compare bexobrutideg, a BTK degrader, with pirtobrutinib in relapsed/refractory CLL/SLL patients who previously received covalent BTK inhibitors. The study aims to demonstrate bexobrutideg's superiority, with primary endpoints of ORR and PFS. This marks the first Phase 3 trial for bexobrutideg, targeting a new treatment approach for CLL.
08-04 05:00
赛诺菲旗下3批次流感病毒裂解疫苗获广东药检院予以签发
8月3日消息，国家药品监督管理局旗下广东省药品检验所披露的生物制品批签发产品公示情况显示，2026年7月27日至2026年8月2日，广东省药品检验所对3批次流感...
08-03 20:16
